Overview

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
RECRUITING
Trial end date:
2029-04-16
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel